LOAMS
Lombard Odier Asset Management (Switzerland) Portfolio holdings
AUM
$1.98B
This Quarter Return
+5.43%
1 Year Return
+25.93%
3 Year Return
+103.45%
5 Year Return
+160.5%
10 Year Return
+469.02%
AUM
$1.57B
AUM Growth
+$1.57B
(-2.7%)
Cap. Flow
-$30.3M
Cap. Flow
% of AUM
-1.93%
Top 10 Holdings %
Top 10 Hldgs %
22.89%
Holding
432
New
226
Increased
52
Reduced
94
Closed
41
Top Buys
| 1 |
CIXX
CI Financial Corp.
CIXX
|
$22.4M |
| 2 |
CRISPR Therapeutics
CRSP
|
$13.5M |
| 3 |
Virtus Investment Partners
VRTS
|
$11.9M |
| 4 |
Amazon
AMZN
|
$11.8M |
| 5 |
Medifast
MED
|
$11.5M |
Top Sells
| 1 |
Merck
MRK
|
$27.7M |
| 2 |
Voya Financial
VOYA
|
$24.9M |
| 3 |
Equity Lifestyle Properties
ELS
|
$23.4M |
| 4 |
BioNTech
BNTX
|
$16.1M |
| 5 |
iShares MSCI India ETF
INDA
|
$15.5M |
Sector Composition
| 1 | Healthcare | 52.77% |
| 2 | Consumer Discretionary | 15.05% |
| 3 | Financials | 13.41% |
| 4 | Technology | 7.21% |
| 5 | Industrials | 3.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BHVN
26
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $24.1M | 1.54% |
175,176
-27,835
| -14% | -$3.84M |
|
27
10x Genomics
TXG
$1.74B
| $23.2M | 1.48% |
155,952
+13,180
| +9% | +$1.96M |
|
28
Neurocrine Biosciences
NBIX
$13.8B
| $22.4M | 1.43% |
262,665
+22,682
| +9% | +$1.93M |
|
29
Natera
NTRA
$23.1B
| $21.8M | 1.39% |
233,117
+19,717
| +9% | +$1.84M |
|
30
Apple
AAPL
$3.45T
| $21.5M | 1.37% |
121,190
-29,401
| -20% | -$5.22M |
|
31
Apellis Pharmaceuticals
APLS
$3.48B
| $20M | 1.28% |
423,676
+216,930
| +105% | +$10.3M |
|
32
iRhythm Technologies
IRTC
$5.46B
| $19M | 1.21% |
161,343
+61,571
| +62% | +$7.25M |
|
33
Teladoc Health
TDOC
$1.37B
| $18.8M | 1.2% |
204,539
+17,264
| +9% | +$1.59M |
|
34
Iovance Biotherapeutics
IOVA
$807M
| $18.1M | 1.16% |
949,884
+80,344
| +9% | +$1.53M |
|
|
MRTX
35
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $17.9M | 1.14% |
121,736
+28,579
| +31% | +$4.19M |
|
36
Microsoft
MSFT
$3.77T
| $17.3M | 1.11% |
51,555
-10,623
| -17% | -$3.57M |
|
37
Fate Therapeutics
FATE
$120M
| $15.9M | 1.02% |
272,011
+145,101
| +114% | +$8.49M |
|
38
Twist Bioscience
TWST
$1.63B
| $15.5M | 0.99% |
200,158
-16,726
| -8% | -$1.29M |
|
39
Allogene Therapeutics
ALLO
$251M
| $14.9M | 0.95% |
996,116
+81,700
| +9% | +$1.22M |
|
|
RCM
40
DELISTED
R1 RCM Inc. Common Stock
RCM
| $14.7M | 0.94% |
577,798
+48,872
| +9% | +$1.25M |
|
|
MDRX
41
DELISTED
Veradigm Inc. Common Stock
MDRX
| $14.6M | 0.93% |
791,161
-349,314
| -31% | -$6.44M |
|
42
Pool Corp
POOL
$11.6B
| $14.2M | 0.91% |
25,167
-5,607
| -18% | -$3.17M |
|
43
Exact Sciences
EXAS
$8.98B
| $13.9M | 0.89% |
178,148
-113,153
| -39% | -$8.81M |
|
|
44
CRISPR Therapeutics
CRSP
$4.71B
| $13.5M | 0.86% |
+177,769
| New | +$13.5M |
|
45
Intellia Therapeutics
NTLA
$1.22B
| $13.4M | 0.86% |
113,311
-35,495
| -24% | -$4.2M |
|
|
NVTA
46
DELISTED
Invitae Corporation
NVTA
| $12.1M | 0.77% |
790,396
+66,854
| +9% | +$1.02M |
|
47
InMode
INMD
$944M
| $12M | 0.77% |
170,000
+70,000
| +70% | +$4.94M |
|
|
48
Virtus Investment Partners
VRTS
$1.36B
| $11.9M | 0.76% |
+40,000
| New | +$11.9M |
|
|
49
Amazon
AMZN
$2.44T
| $11.8M | 0.75% |
+3,525
| New | +$11.8M |
|
50
Sangamo Therapeutics
SGMO
$157M
| $11.6M | 0.74% |
1,539,994
+130,258
| +9% | +$977K |
|